Abstract
Chewy, Inc. will release fiscal first-quarter results on June 10, 2026 Pre-Market; consensus currently points to revenue of 3.36 billion US dollars and adjusted EPS of 0.25, setting the stage for a margin- and mix-focused report that could hinge on updated commentary around healthcare expansion, Autoship trends, and cost discipline.Market Forecast
Consensus for the current quarter calls for revenue of 3.36 billion US dollars, implying year-over-year growth of 9.12%, with adjusted EPS expected at 0.25, up 28.98% year over year; EBIT is forecast at 144.20 million US dollars, up 57.28% year over year. Forecast disclosures do not include a gross margin or net margin outlook, and net income expectations are framed instead through EBIT and EPS.Chewy, Inc.’s core business—sale of pet products and services supported by high-recurring Autoship orders—drove essentially all of last quarter’s 3.26 billion US dollars in revenue, which increased 0.53% year over year. The most promising near-term growth vector remains healthcare and services, where the planned addition of Modern Animal is expected to contribute more than 125.00 million US dollars on an annualized basis once consolidated; in the interim, overall revenue growth of 9.12% year over year sets the baseline against which contributions will be assessed as the business scales.
Last Quarter Review
In the prior quarter, Chewy, Inc. reported revenue of 3.26 billion US dollars (up 0.53% year over year), a gross profit margin of 29.40%, GAAP net profit attributable to the company of 39.20 million US dollars and a net profit margin of 1.20%, while adjusted EPS was 0.09 (up 80.00% year over year).A notable highlight was profitability leverage: EBIT reached 42.50 million US dollars, representing 537.60% year-over-year expansion and a modest beat versus street expectations. On the business side, the company’s single consolidated revenue line—sale of pet products and services—accounted for the entire 3.26 billion US dollars in quarterly revenue, reflecting 0.53% year-over-year growth amid a stabilizing demand mix anchored by Autoship.
Current Quarter Outlook (with major analytical insights)
Core Commerce: Consumables and Supplies
The core commerce engine remains the decisive determinant of this quarter’s print given its scale and recurring profile. With consensus penciling in revenue of 3.36 billion US dollars (up 9.12% year over year), the setup implies an acceleration versus last quarter’s 0.53% year-over-year top-line growth, which will invite scrutiny of unit volumes, pricing carryover, and the cadence of order frequency across Autoship customers. The company’s adjusted EPS forecast of 0.25 (up 28.98% year over year) and EBIT of 144.20 million US dollars (up 57.28% year over year) suggest operating leverage is expected to reappear as growth normalizes, provided gross margin holds within a tight band and fulfillment costs remain contained.Autoship dynamics are likely to play an outsized role in the quarter’s quality-of-revenue narrative. Analysts point to approximately 85% of net sales coming from Autoship customers, implying last quarter’s recurring revenue base around 2.78 billion US dollars out of the 3.26 billion US dollars total. If order frequency and retention metrics remain resilient, Chewy, Inc. could realize a favorable mix of repeat purchases that supports contribution profit per order even as category trends remain mixed. With last quarter’s gross margin at 29.40%, investors will look for evidence that the merchandising mix, private labels, and inbound freight normalization together help sustain or gradually expand margin dollars.
On costs, the company’s prior commentary and reported initiatives around operational optimization and automation are increasingly relevant. Management has signaled that technology and process streamlining can yield meaningful savings; external commentary has even highlighted an AI-focused cost program expected to save tens of millions of dollars this year. In the context of a 57.28% year-over-year EBIT growth forecast, follow-through on these savings—alongside improved warehouse productivity and shipping efficiency—could help explain the anticipated operating leverage. The key watch items are fulfillment expense per order, stock-outs, and the balance between promotional intensity and margin protection.
Healthcare and Services: Chewy Vet Care and the Modern Animal Integration
Chewy, Inc.’s most promising adjacency remains healthcare and services, where the company has agreed to acquire Modern Animal. The transaction is expected to lift the clinic footprint from 18 to 47 locations and add more than 125.00 million US dollars in annualized revenue when fully incorporated. While the company has indicated it will update financial guidance after the deal closes—expected during fiscal Q2—the near-term narrative impact is already notable: this line of business tends to carry higher gross margins, support cross-sell into pharmacy and wellness products, and increase lifetime value by strengthening customer engagement.From a near-term modeling standpoint, the Modern Animal contribution will be limited in the quarter being reported, but the signaling effect matters for valuation. The company has stated the acquisition should be EPS-accretive within the first year post-close and EBITDA dollar-neutral on a pro forma basis in fiscal 2026, with revenue contribution starting in 2027. For the quarter at hand, investors will therefore focus on disclosures around Chewy Vet Care utilization rates, scheduling capacity, and clinic-level economics. Any commentary that quantifies ramp timing or unit economics for the expanded footprint could refine longer-horizon margin and cash flow expectations.
Strategically, layering clinical services on top of the existing e-commerce base creates multiple cross-traffic pathways—prescriptions, tele-triage, wellness plans—and can support premiumization without resorting to aggressive price increases on staples. Even a small near-term revenue base in clinics can deliver disproportionate impact if it unlocks stronger pharmacy adherence and higher net sales per active customer on the core site. Given the quarter’s forecasted 9.12% revenue growth and 57.28% growth in EBIT, incremental proof that services are becoming a meaningful mix tailwind may be a swing factor in post-earnings sentiment.
Key Stock Price Drivers Around the Print
Three clusters will likely dictate the share reaction: the interplay of growth and margins versus consensus, updated commentary on customer and category trends, and capital allocation signals. First, growth-versus-margin quality will be dissected. If revenue lands near 3.36 billion US dollars and adjusted EPS approximates 0.25, investors will probe the gross profit dollar build, fulfillment cost per order, and any sequential change in gross margin from last quarter’s 29.40%. With EBIT expected to rise 57.28% year over year, evidence of durable operating leverage—not merely temporary expense timing—will be necessary for the stock to re-rate materially.Second, forward tone on customers and demand will be key. Alternative-data tracking and recent analyst commentary suggest near-term category softness and a cautious consumer environment, implying a risk that growth skews toward consumables rather than discretionary categories. Management’s qualitative color on active customer trends, net sales per active customer, and Autoship retention could either validate or ease those concerns. If the company indicates stable cohort behavior and continued repeat purchase strength, even an in-line revenue outcome might be interpreted constructively, provided margin performance corroborates the thesis.
Third, capital deployment and corporate actions can shape the near-term equity narrative. The board’s authorization to add 500.00 million US dollars to the share repurchase program highlights an intention to balance growth investment with shareholder returns. Updates on repurchase activity, free cash flow conversion, and the integration timetable for Modern Animal will inform expectations for full-year capital allocation. Additionally, any management commentary that quantifies ongoing technology-driven cost savings—including automation and AI-enabled efficiencies—could strengthen the margin-improvement narrative into the back half. Conversely, a reiteration of cautious category trends without incremental margin offsets or clear execution milestones might dampen the near-term multiple, even if headline results meet estimates.
Analyst Opinions
Bullish views comprise the clear majority among recently published opinions. Multiple institutions maintain positive stances anchored in valuation support, margin catalysts from mix and cost programs, and the optionality of healthcare expansion.- Morgan Stanley reaffirmed an Overweight rating while trimming its price target to 43.00 US dollars. The firm acknowledged a softer near-term category backdrop and rising cost headwinds but argued that the stock’s sharp pullback already embeds many of these challenges, with investor expectations now appearing too pessimistic relative to the company’s longer-term earnings power. The note highlights that, even with cautious adjustments to organic growth assumptions for fiscal 2026, the combination of recurring revenue quality and margin levers can support a constructive risk-reward skew.
- RBC reiterated an Outperform rating and raised its price target to 47.00 US dollars following the prior report. The bank’s thesis emphasizes improving profitability momentum—evidenced by a step-up in EBIT—and sees room for gross profit dollar expansion as the merchandising mix solidifies and healthcare initiatives start to scale. Against a backdrop of anticipated 9.12% year-over-year revenue growth and an expected 28.98% increase in adjusted EPS for the current quarter, RBC expects the cadence of margin improvement to remain the central driver of estimate revisions.
- Piper Sandler maintained a Buy rating with a 48.00 US dollars price target, citing a constructive view on operating efficiency and the durability of recurring demand patterns. The firm’s framework points to potential upside if management demonstrates tighter fulfillment costs and incremental margin contribution from technology-enabled process enhancements, which could translate to sustained EBIT leverage beyond the near term.
- Raymond James upgraded the shares to Outperform, calling the valuation too compelling to ignore after the equity’s decline. The upgrade case suggests the setup into this print features a relatively low bar on the top line and credible opportunities to expand margins into 2026 as services scale and cost initiatives take hold. The extension of the buyback authorization further underscores management’s confidence in cash generation, which the firm views as supportive of the current investment case.
- William Blair reiterated a Buy view, focusing on the strategic expansion into higher-margin veterinary services and the signaling effect of additional share repurchases. Their analysis frames the services roadmap as a medium-term accelerant to blended margins and argues that the company’s track record in building customer engagement can support higher net sales per active customer as clinics and pharmacy offerings deepen integration with the core platform.
- TD Cowen also reaffirmed a Buy stance ahead of the reporting date, indicating expectations for solid execution and a constructive trajectory on profitability. The thesis aligns with consensus forecasts for year-over-year growth in revenue and EPS and underscores the importance of consistent Autoship performance in underpinning margin stability.
The common thread across these bullish perspectives is that near-term category noise appears manageable in light of counterbalancing levers: a large recurring revenue base, emerging healthcare contributions that should carry favorable unit economics, and a tangible cost-savings program that can bolster EBIT. Forecasts for the quarter—3.36 billion US dollars of revenue, adjusted EPS of 0.25, and EBIT of 144.20 million US dollars—imply that the path to improved profitability is beginning to materialize in the reported numbers. Where the opinions converge most is on the idea that valuation embeds conservative growth assumptions and that incremental proof points on margin execution and healthcare scaling could catalyze re-rating.
In practical terms, the majority view expects the following to shape the equity reaction: whether the company can translate recurring demand into gross profit dollar gains without escalating promotional intensity; whether fulfillment and operating cost ratios reflect the early benefits of process and AI-driven efficiencies; and whether management’s update on services expansion credibly connects near-term investments to medium-term margin uplift. If results and commentary substantiate these points, bullish institutions anticipate that the shares can begin to reflect a more balanced appraisal of growth durability and profitability momentum.
Comments